Precision Delivery and the Cost of Revision Surgery

The BioTrinity conference, organized by BioUK, highlighted a spectrum of cell and protein-based therapies alongside novel delivery methods at the recent meeting. The focus was not just on new therapeutic candidates, but on solving the fundamental problem of how these molecules are retained in the body.

The inefficiency of current treatments is a massive economic and clinical burden. For patients undergoing spinal fusions after trauma or sports injuries, existing formulations of BMP-2 are poorly retained around the spine. This lack of retention causes inflammation or bone growth outside the spine, often necessitating revision surgery at a cost of up to $50,000. The risks are high enough that the use of BMP-2 in the cervical spine has resulted in a black box warning due to breathing difficulties caused by bone and inflammation.

Renovos Biologics, a University of Southampton spin-out, is addressing this through synthetic nanoclays. Rather than using nanoclays for traditional drug release control, they are utilizing them for medical delivery. Their RENOVITE® technology provides an injectable, biodegradable nanoclay designed to retain the BMP-2 bioactive molecule until newly regenerated tissue replaces it.

This approach changes the mechanics of bone formation. By using a 23-gauge needle to deliver BMP-2 in a gel, the company aims to allow precise templating of new bone formation. This prevents the "eggshell effect" where bone grows only on the outside of the fusion, instead promoting better quality growth that moves through the fusion.

The implications for market expansion are clear. Because the nanoclay retains the protein more readily, it is possible to administer BMP-2 in a lower dosage. This creates potential benefits for use in lower-cost markets. The clinical need remains high, particularly as 45-year-old patients and younger represent a significant demographic in lumbar fusions.

The success of these delivery platforms will depend on whether they can move beyond the laboratory to prove that localized retention translates to reduced surgical complications in a broader patient population.